President Biden urged Congress in his State of the Union message Tuesday night to cap monthly cost sharing for insulin at $35 and let Medicare negotiate what it pays for prescription drugs.
Biden said cutting the cost of prescription drugs
…
Articles by : Tom Mirga, Editor at Large
Thirteen congressional Democrats—eight senators and five representatives—asked Pharmaceutical Research and Manufacturers of America (PhRMA) to respond by March 8 to questions about “rapid price hikes affecting the vast majority of popular brand name drugs.”
Sens. Elizabeth Warren (Mass.) and Amy
…
The federal government indicated in a court filing last week that it will appeal the court’s decision striking down and vacating the government’s letter telling drug company AstraZeneca its conditions on 340B pricing when covered entities use contract pharmacy were
…
340B provider and drug industry stakeholders joined yesterday in congratulating U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as Director of the U.S. Office of Pharmacy Affairs, the federal agency that runs the 340B drug pricing program.
…
A Democratic push in Congress to cap insulin costs for patients is gaining momentum. It may be a sign that some in the party are giving up on trying to pass comprehensive drug pricing legislation and focusing now on trying
…Breaking News
HRSA Picks Federal HIV/AIDS Policy Specialist Emeka Egwim To Be its Next 340B Program Director
Emeka Egwim, a federal government HIV/AIDS policy specialist who also has served in the Medicaid Drug Rebate Program, is the new head of the federal 340B Drug Pricing Program.
In a letter this morning to its staff, the U.S. Health
…
The U.S. Health Resources and Services Administration’s (HRSA) proposed replacement for its year-old 340B administrative dispute resolution (ADR) process has been under White House review for almost 100 days—nearly a month longer that the anticipated release date announced in November.
…
The U.S. Health Resources and Services Administration’s (HRSA) recent statement that only three hospitals so far have said on a federal form that they lost their 340B eligibility due to fallout from COVID-19 does not reflect the problem’s much bigger
…
The National Rural Health Association (NRHA) asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week to act against drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.
NRHA CEO Alan Morgan also urged Becerra
…
New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s
…